KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:开放图源暂不可得 入排置信度 0.85

Radiotherapy quality assurance of patients with squamous cell carcinoma of the head and neck included in the DAHANCA 19 randomised phase III trial.

C R Hansen, E Samsøe, B Smulders, H M B Sand, A I S Holm, T Furre, K Jensen, J Johansen, C Maare, C A Kristensen, M Andersen, Å Bratland, C Grau, J G Eriksen, J Overgaard

Radiother Oncol 211 111096

PMID40825443
PMCID-
DOI10.1016/j.radonc.2025.111096
发表日期2025-08-18
入排依据:Report is a secondary analysis of radiotherapy quality assurance from a Phase III trial. While it meets basic eligibility criteria (oncology, human, randomized, phase 3, drug intervention), it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). It is an original report of a sub-study focusing on compliance and quality assurance, not the primary efficacy analysis.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 当前未获得可用 PubMed/PMC Figure 图源,建议后续从出版商页补图源。
摘要

摘要

BACKGROUND AND PURPOSE: The current study investigates the radiotherapy quality assurance (QA) of the DAHANCA 19 randomised phase III trial comparing standard chemo-radiotherapy with and without Zalutumumab. MATERIAL AND METHODS: The complete radiotherapy datasets for 608 patients were collected centrally. QA parameters were extracted, including dose to the primary target volume, spinal cord and brainstem, and overall treatment time. These parameters were compared to DAHANCA RTQA guidelines and categorised into no, minor or major deviations. RESULTS: Among the 608 patients eligible for analyses, 118 had one minor deviation, 20 had two minor, and two had three minor deviations. Fifteen patients (2.5 %) had major deviations, with 13 related to overall treatment time or high-dose target volume coverage. Of the major deviations, 12 were in the experimental arm, and 3 were in the control arm (p = 0.02). Most major deviations were deemed clinically unavoidable and, therefore, not considered violations of clinical practice. There was no difference in outcomes between patients with minor deviations and those without deviations, aligning with current definitions and guidelines. Patients with major deviations did not have inferior loco-regional or disease-specific survival compared to those without deviations. However, they had significantly worse survival, which was not attributed to radiotherapy. CONCLUSIONS: The treatment plans in DAHANCA 19 adhered well to national guidelines. Most major deviations were observed in the experimental arm but did not affect the local treatment control. No indication that compromised RT-QA affected the conclusions of DAHANCA 19 was found.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。